OP0003 Single arm, multicentre, phase 2 study of clofarabine in Chinese paediatric patients with refractory or relapsed acute lymphoblastic leukaemia

l p zhang,jayu lu,x du,yang li,zhiming cai,k yu,f l tan,y fang,x j huang

DOI: https://doi.org/10.1016/j.ejca.2014.03.021

IF: 10.002

2014-01-01

European Journal of Cancer

Abstract:Background A phase 2 study was done to evaluate the safety and efficacy of clofarabine in paediatric patients with refractory or relapsed acute lymphoblastic leukaemia (ALL) in China. Methods Patients aged 1–21 years with histologically confirmed, relapsed or refractory ALL were eligible. Clofarabine was administered intravenously for 5 days at 52 mg/m2 per day during induction and consolidation. The primary endpoint was overall remission rate (ORR; complete remission [CR] plus CR with incomplete counts [CRi]). Blood samples were collected for pharmacokinetic analysis. Findings A total of 44 patients were enrolled, of whom 43 were evaluable for response. The median age was 13 years (range 5–22 years), and the majority were B cell-ALL (75%, 33/44). The ORR was 44.2% (19/43), including two CR and 17 CRi. 39 patients had progressive disease at cut-off time; the overall median remission duration was 2.9 months, and 3.4 months for patients achieved CR or CRi. Subgroup analysis showed that efficacy differed significantly by age and phenotype of the cell (age <14 years versus age ⩾14 years: 60.9% versus 25%, p = 0.0308; B-cell ALL versus T-cell ALL: 57.6% versus 0, p = 0.002). The most common (⩾10%) adverse reactions (ADRs) were haematological toxicity, gastrointestinal reaction, and abnormal liver function, and the most common grade 3 or 4 non-haematological ADR was ALT elevation (13.6%). PK analysis showed that after multiple administrations the mean elimination half-life of clofarabine was 6.43 h, and the Tmax was around 2 h. The mean Cmax and exposure to clofarabine over the dosing period (AUC 0–24) were 581 μg/L and 2602.56 μg/L, respectively. Interpretation Single-agent clofarabine treatment is effective in Chinese paediatric patients with multiple relapsed or refractory ALL, with an acceptable safety profile. A phase 2 study was done to evaluate the safety and efficacy of clofarabine in paediatric patients with refractory or relapsed acute lymphoblastic leukaemia (ALL) in China. Patients aged 1–21 years with histologically confirmed, relapsed or refractory ALL were eligible. Clofarabine was administered intravenously for 5 days at 52 mg/m2 per day during induction and consolidation. The primary endpoint was overall remission rate (ORR; complete remission [CR] plus CR with incomplete counts [CRi]). Blood samples were collected for pharmacokinetic analysis. A total of 44 patients were enrolled, of whom 43 were evaluable for response. The median age was 13 years (range 5–22 years), and the majority were B cell-ALL (75%, 33/44). The ORR was 44.2% (19/43), including two CR and 17 CRi. 39 patients had progressive disease at cut-off time; the overall median remission duration was 2.9 months, and 3.4 months for patients achieved CR or CRi. Subgroup analysis showed that efficacy differed significantly by age and phenotype of the cell (age <14 years versus age ⩾14 years: 60.9% versus 25%, p = 0.0308; B-cell ALL versus T-cell ALL: 57.6% versus 0, p = 0.002). The most common (⩾10%) adverse reactions (ADRs) were haematological toxicity, gastrointestinal reaction, and abnormal liver function, and the most common grade 3 or 4 non-haematological ADR was ALT elevation (13.6%). PK analysis showed that after multiple administrations the mean elimination half-life of clofarabine was 6.43 h, and the Tmax was around 2 h. The mean Cmax and exposure to clofarabine over the dosing period (AUC 0–24) were 581 μg/L and 2602.56 μg/L, respectively. Single-agent clofarabine treatment is effective in Chinese paediatric patients with multiple relapsed or refractory ALL, with an acceptable safety profile.